Red X iconGreen tick iconYellow tick icon

Contact Details

Phone
64 3 474 0999
Email
michael.schultz@otago.ac.nz
Position
Professor and Gastroenterologist
Department
Department of Medicine (Dunedin)
Qualifications
MD PhD
Research summary
Intestinal epithelial function in health and disease
Teaching
  • MICN2 and 3: SIS, Systems Integration Course (until 2008)
  • MICN2/3: Clinical advisor in Gastroenterology to the Curriculum Development Group
  • MICN3: Clinical Skills Tutor (since 2008)
  • MICN4: clinical teaching and home tutoring, OSLERs, key topics
  • MICN5: intercalated teaching, OSCE
  • Station development in 2008
  • Lead examiner for 2009
  • MICN6: tutorials for trainee interns
  • MICN5: Mentor, TPER
Clinical

Inflammatory Bowel Disease

Research

Michael Schultz has a special interest in inflammatory bowel diseases and related disorders both on a clinical and basic research level. As director of the Gut Health Network, a research theme of the University of Otago, he is involved in a variety of projects. Basic science: The research group is located in the Department of Physiology in the laboratory of Associate Professor Grant Butt and works on the role of epithelium in intestinal inflammation with the use of human organoids, animal models and cell cultures. Collaborations with the Department of Microbiology and Immunology support these projects. Professor Schultz is involved in several epidemiological and therapeutic projects involving patients with irritable bowel syndrome, coeliac disease, and non-alcoholic fatty liver disease.

Publications

Mcnamara, J., Wilson, W., Pipicella, J. L., Ghaly, S., Gearry, R., Begun, J., … Schultz, M., … Connor, S. J. (2024). Fistulising Crohn's Disease in a large Australasian cohort: Crohn's Colitis Cure (CCC) Data Insights Program. Journal of Crohn's & Colitis, 18(Suppl. 1), P1129. doi: 10.1093/ecco-jcc/jjad212.1259 Conference Contribution - Published proceedings: Abstract

Barnett, M., Mcnamara, J., Wilson, W., Pipicella, J., Ghaly, S., Gearry, R., … Schultz, M., … Andrews, J. M. (2024). Dose escalated Ustekinumab in Inflammatory Bowel Disease: Crohn's Colitis Cure (CCC) Data Insights Program. Journal of Crohn's & Colitis, 18(Suppl. 1), P1012. doi: 10.1093/ecco-jcc/jjad212.1142 Conference Contribution - Published proceedings: Abstract

Alshiwanna, B., Mcnamara, J., Wilson, W., Pipicella, J. L., Ghaly, S., Gearry, R., … Schultz, M., … Andrews, J. M. (2024). Dose escalated Infliximab in Inflammatory Bowel Disease: Crohn's Colitis Cure (CCC) Data Insights Program. Journal of Crohn's & Colitis, 18(Suppl. 1), P1005. doi: 10.1093/ecco-jcc/jjad212.1135 Conference Contribution - Published proceedings: Abstract

Mcnamara, J., Alshiwanna, B., Wilson, W., Pipicella, J. L., Ghaly, S., Gearry, R., … Schultz, M., … Connor, S. J. (2024). Dose escalated vedolizumab in Inflammatory Bowel Disease: Crohn's Colitis Cure (CCC) Data Insights Program. Journal of Crohn's & Colitis, 18(Suppl. 1), P959. doi: 10.1093/ecco-jcc/jjad212.1089 Conference Contribution - Published proceedings: Abstract

Pipicella, J. L., McNamara, J., Wilson, W., Lynch, K., Walker, G., Begun, J., … Gearry, R., Schultz, M., … Connor, S. J. (2024). The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn's Colitis Cure (CCC) data insights program. Journal of Crohn's & Colitis, 18(Suppl. 1), P880. doi: 10.1093/ecco-jcc/jjad212.1010 Conference Contribution - Published proceedings: Abstract

Back to top